PFG Investments LLC makes a new $346,000 investment in Solventum Co. (NYSE:SOLV)

PFG Investments LLC acquired a new stake in Solventum Co. (NYSE:SOLV – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 6,543 shares of the company’s stock, valued at approximately $346,000.

A number of other institutional investors have also made changes to their positions in SOLV. Ashton Thomas Private Wealth LLC bought a new stake in Solventum during the second quarter valued at about $211,000. Cahill Financial Advisors Inc. bought a new stake in shares of Solventum in the second quarter valued at about $292,000. LSV Asset Management bought a new stake in shares of Solventum in the second quarter valued at about $164,000. Financial Gravity Asset Management Inc. acquired a new stake in shares of Solventum in the second quarter valued at $180,000. Finally, Acadian Asset Management LLC bought a new position in Solventum in the second quarter worth $1,774,000.

Solventum price performance

Shares of SOLV stock opened at $68.65 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.31, and a debt-to-equity ratio of 2.90. Solventum Co. has a one year low of $47.16 and a one year high of $96.05. The stock has a 50-day moving average of $58.32.

Solventum (NYSE:SOLV – Get Your Free Report ) last issued its quarterly earnings data on Thursday, August 8th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.10. The company had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.05 billion. The company’s quarterly revenue was up 0.2% compared to the same quarter last year. As a group, research analysts forecast that Solventum Co. will post 6.38 earnings per share for the current year.

Analysts on Wall Street are forecasting an increase

Several analysts have issued reports on SOLV shares. Bank of America cut their price target on shares of Solventum from $70.00 to $60.00 and set a “neutral” rating on the stock in a research report on Tuesday, June 25th. BTIG Research began coverage on Solventum in a report on Thursday, September 5th. They issued a “neutral” rating on the company. Goldman Sachs Group lifted their price objective on Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a report on Monday, August 12th. Morgan Stanley reduced their price target on Solventum from $70.00 to $55.00 and set an “equal weight” rating for the company in a research note on Monday, July 15th. Finally, Wells Fargo & Company cut their price target on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a research note on Friday, 9 August. One research analyst has rated the stock with a sell rating and six have given a hold rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $58.25, based on data from MarketBeat.

Check out the latest stock analysis on SOLV

Solventum Company Profile

(Free Report)

Solventum Corporation, a healthcare company, is committed to developing, manufacturing and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems and Purification and Filtration.

Featured stories

Want to see what other hedge funds own SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Solventum Co. (NYSE: SOLV – Free Report).

Get Solventum Daily news and reviews – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Solventum and related companies with MarketBeat.com ‘s FREE daily email newsletter.